Loading...
Market
Will BioNTech's stock price recover to its pre-Q2 earnings report level by December 31, 2024?
3
Resolution / Starting Odds
Yes • 50%
No • 50%
Stock price data from financial markets (e.g., NASDAQ, NYSE)
Story
BioNTech Reports Significant Q2 Loss, Stock Slides 4%, Guidance Reiterated
Aug 5, 2024, 10:21 AM
BioNTech reported a significant quarterly loss in the second quarter of 2024, driven by a sharp decline in COVID-19 vaccine sales and increased investment in new product development. The company posted a net loss of €807.8 million, or €3.36 per share, compared to analysts' expectations of a €2.01 loss per share. Revenues for the quarter were €128.7 million, slightly below the estimated €131.64 million. BioNTech invested €525.6 million, approximately 90% of its total R&D spend, in non-COVID-19 related activities, primarily oncology and mRNA projects. This strategic shift towards cancer treatments comes as the company faces reduced demand for its COVID-19 vaccines. BioNTech's stock slid 4% after the earnings report, and the company reiterated its full-year guidance.
View original story
Similar markets
Below $100 • 25%
$100 - $150 • 25%
$150 - $200 • 25%
Above $200 • 25%
Increase by more than 20% • 25%
Increase by 10-20% • 25%
Increase by less than 10% • 25%
No increase or decrease • 25%
Outperform by more than 5% • 25%
Perform within 5% of S&P 500 • 25%
Underperform by 1-5% • 25%
Underperform by more than 5% • 25%
